Key Takeaways
- Compound: Retatrutide (6.0-day half-life, GLP-1/GIP/glucagon triple agonist)
- Protocol length: 24 weeks covering 5 dosing phases
- Steady state: Reached in approximately 4.3 weeks at each dose level
- Titration approach: Gradual dose increases allow your body to adjust at each level before escalating
Investigational Drug: Retatrutide is not FDA-approved and is currently in Phase 3 clinical trials. FDA approval is expected in 2027. The dosing data below is based on Phase 2/3 trial protocols published in the New England Journal of Medicine.[1]
Retatrutide Conservative Titration: 1mg Start, Slow Escalation
Quick Answer
Retatrutide has a half-life of 6.0 days. This 24-week titration protocol starts at 1mg and gradually increases to 12mg, reaching steady state at each dose level in approximately 4.3 weeks. Gradual titration is the standard approach because it allows your body to adjust before each increase, which helps manage side effects.
Data computed using GLP3Planner's pharmacokinetic model based on published clinical trial parameters.
Understanding This Titration Protocol
A titration protocol is a structured approach to gradually increasing your dose over time. The idea is simple: start low, give your body time to adapt, then increase. Each dose level lasts long enough for the drug to reach steady state, the point where the amount entering your system with each dose roughly equals the amount being eliminated between doses.
For Retatrutide with its 6.0-day half-life, steady state takes approximately 4.3 weeks of consistent dosing at the same level. That is why the protocol holds each dose for at least 4 weeks before escalating. Rushing through the titration is the most common cause of intolerable gastrointestinal side effects like nausea and vomiting.[1]
This protocol covers 5 phases over 24 weeks. The pharmacokinetic data below shows you exactly what happens at each phase: how drug levels accumulate, what your peak and trough values look like, and how long stabilization takes. All calculations use GLP3Planner's PK model, which is based on published clinical trial half-life data.
Dosing Protocol
| Phase | Weeks | Dose | Frequency | Peak (mg) | Trough (mg) | Syringe Units |
|---|---|---|---|---|---|---|
| Initial | 1-4 | 1mg | 1x/week | 1.73 | 0.87 | 20 IU |
| Step 2 | 5-8 | 2mg | 1x/week | 3.53 | 1.77 | 40 IU |
| Step 3 | 9-12 | 4mg | 1x/week | 7.07 | 3.53 | 80 IU |
| Step 4 | 13-16 | 8mg | 1x/week | 14.14 | 7.07 | 160 IU |
| Maintenance | 17-24 | 12mg | 1x/week | 21.63 | 10.81 | 240 IU |
Peak and trough values are modeled using a 6.0-day half-life from published clinical data. See methodology.
What the Numbers Mean
The table above shows modeled drug levels at each phase of this protocol. Here is what each column tells you:
Peak (mg)
The highest amount of Retatrutide in your body, measured right after an injection at steady state for that dose level. Higher peaks are associated with stronger appetite suppression but also more pronounced side effects, especially nausea.
Trough (mg)
The lowest amount remaining just before your next injection. This is the minimum drug level your body maintains between doses. The trough determines whether you still have therapeutic coverage throughout the dosing interval.
Steady State (~4.3 weeks)
The point where drug accumulation stabilizes. Before steady state, each dose adds more drug than your body eliminates, so levels keep climbing. Once reached, the amount in equals the amount out, and your peaks and troughs become consistent from week to week.
These are population-average estimates based on clinical trial data. Individual levels vary based on body composition, metabolism, and injection site. For a personalized view, enter your actual doses into the Retatrutide calculator.
Pharmacokinetic Summary
Half-Life
6.0 days
Time for 50% of the drug to be eliminated
Steady State
~4.3 weeks
Time to reach stable peak/trough levels at each dose
Final Peak Level
21.63 mg
Peak drug amount at the maintenance dose
Model Your Own Schedule
Enter your actual doses and timing to see a personalized PK curve with your real data.
Open Retatrutide CalculatorReconstitution Reference
Based on a 10mg vial with 2mL BAC water (5mg/mL):
| Dose | Syringe Units (U-100) | Volume (mL) |
|---|---|---|
| 1mg | 20 IU | 0.2mL |
| 2mg | 40 IU | 0.4mL |
| 4mg | 80 IU | 0.8mL |
| 8mg | 160 IU | 1.6mL |
| 12mg | 240 IU | 2.4mL |
Need a different concentration? Use our reconstitution calculator. For step-by-step instructions, see the Retatrutide reconstitution guide.
Practical Tips for This Protocol
Managing Each Dose Level
Titration is about finding the dose that works for you, not about reaching the maximum as fast as possible. Many people find their optimal dose well below the highest level in the protocol.
- First 1-2 weeks at each new dose: Expect the strongest side effects during this period. Eating smaller meals and staying hydrated helps. Some people prefer evening injections to sleep through the initial peak.
- Weeks 3-4 at each dose: Side effects typically ease as your body adapts. If they have not improved by week 4, consider holding at this dose for another 2-4 weeks before escalating.
- When to hold (not escalate): Persistent nausea lasting more than 3 days after injection, ongoing GI issues, or rapid weight loss (more than 1.5 kg per week consistently) are all reasons to stay at your current dose longer.
- Injection timing: Pick the same day each week. Consistent timing produces the most predictable drug levels.
Common Side Effects
In Phase 2 trials, the most common side effects of retatrutide were gastrointestinal: nausea (35-60% depending on dose), diarrhea (20-40%), and constipation (20-30%). These effects were most pronounced during the first 1-2 weeks at each new dose level and typically improved with continued use.[1]
Nausea
Most common during the first few days after an injection or dose increase. Smaller meals, bland foods, and staying hydrated can help. Some people find evening injections reduce daytime nausea.
Digestive Changes
Diarrhea or constipation may occur as the drug slows gastric emptying. Adequate fiber, water, and gentle activity help regulate digestion. These effects typically improve within the first 2-3 weeks at each dose.
Reduced Appetite
This is an expected effect, not a side effect. Make sure you are still eating enough protein and nutrients even when appetite is suppressed. Skipping meals entirely can lead to fatigue and muscle loss.
For a comprehensive list including less common effects, see the full Retatrutide side effects guide.
See Your Own Levels
Enter your actual doses and schedule to get a personalized PK curve.
How This Data Was Computed
Levels are modeled using GLP3Planner's pharmacokinetic engine with a 6.0-day half-life (published clinical trial value). The model uses superposition to calculate how weekly doses accumulate over time. Read the full methodology, including clinical data sources and model limitations.
Frequently Asked Questions
How long does Retatrutide stay in your system?
Retatrutide has a half-life of 6.0 days. After your last dose, the drug takes approximately 5 half-lives (30 days) to drop below 3% of peak levels. During this time, effects gradually diminish as the drug clears. Use the Retatrutide calculator to model washout from your specific dose.
What is steady state for Retatrutide?
Steady state is when drug accumulation stabilizes, meaning the amount entering your system each dose roughly equals the amount eliminated between doses. For Retatrutide, this takes approximately 4.3 weeks of consistent dosing at the same level. Once at steady state, your peak and trough levels become predictable from week to week.
Can I titrate faster than 4 weeks per dose level?
The 4-week interval exists because it takes 4.3 weeks to reach steady state at each dose. Titrating faster means you are increasing the dose before fully experiencing the current level, which makes it harder to assess tolerance and increases the likelihood of gastrointestinal side effects. Slower is generally better for tolerability.
How accurate is the pharmacokinetic data on this page?
The data uses population-average parameters from published clinical trials. Individual drug levels vary based on body composition, metabolism, kidney and liver function, and injection site. The model is most useful for understanding accumulation patterns, steady state timing, and comparing dosing approaches rather than predicting exact personal blood levels. See the full methodology for details.
What is the peak-to-trough ratio and why does it matter?
The peak-to-trough ratio measures how much drug levels fluctuate between injections. A ratio of 4:1 means your peak is four times your trough. Higher ratios mean bigger swings, which some people associate with more side effects at peak and reduced coverage at trough. Split dosing reduces this ratio by producing smaller, more frequent peaks.
Is retatrutide FDA-approved?
No. As of 2026, retatrutide is an investigational drug in Phase 3 clinical trials (the TRIUMPH program). FDA approval is expected in 2027. The dosing and pharmacokinetic data used here come from published Phase 2 trial results in the New England Journal of Medicine. Check ClinicalTrials.gov for the latest trial status.
Can I use this data to plan my own dosing schedule?
This data is for informational and educational purposes. It shows modeled drug levels for a specific protocol, which can help you understand what to expect and have informed conversations with your doctor. For a schedule tailored to your exact doses, use the interactive Retatrutide calculator.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340. PubMed
- Novo Nordisk. Ozempic (semaglutide) prescribing information. U.S. Food and Drug Administration. FDA Label
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. U.S. Food and Drug Administration. FDA Label
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400(10366):1869-1881. PubMed
- StatPearls. Pharmacokinetics, Steady State. National Center for Biotechnology Information. NCBI Bookshelf
Medical Disclaimer
This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or recommendations. The pharmacokinetic data shown is modeled from population-average clinical trial parameters and does not predict individual drug levels. Always consult your doctor before starting, adjusting, or stopping any medication.
Related Articles
Retatrutide Dosing Guide
Complete titration schedule with clinical trial data and side effects management.
Microdosing Retatrutide
Split-dose protocols, PK comparisons, and practical techniques.
Retatrutide Reconstitution Guide
Step-by-step reconstitution instructions with calculator.
Retatrutide Side Effects
Common and serious side effects with management strategies.
Retatrutide Hub
Everything about Retatrutide in one place: mechanism, trials, dosing, calculators.
PK Methodology
How GLP3Planner calculates drug levels, with clinical data sources.